Vertex will pay tens of millions to license a controversial CRISPR patent

Vertex Pharmaceuticals has agreed to buy rights to use a dominant CRISPR patent owned by the Broad Institute of Harvard and MIT, avoiding a potential lawsuit over its new gene-editing treatment for sickle-cell disease. The agreement allows Vertex to start selling its treatment, approved last Friday, without fear of patent infringement claims. The one-time treatment…